title: How deadly is seasonal influenza-associated pneumonia? The German Competence Network for Community-Acquired Pneumonia.
abstract: The emergence of new influenza virus subtypes has rekindled the interest in the clinical course and outcome of patients with influenza-associated pneumonia. Based on prospective data from 5,032 patients with community-acquired pneumonia (CAP) included in the German Competence Network for Community-Acquired Pneumonia (CAPNETZ), we studied the incidence, clinical characteristics and outcome of patients with influenza-associated CAP and compared these findings with patients without influenza. Diagnosis relied on a positive PCR for influenza in throat washings. 160 patients with influenza-associated CAP were identified (3.2% of total population, 12% of those with defined aetiology). 34 (21%) patients with seasonal influenza had a concomitant pathogen (mostly Streptococcus pneumoniae). Patients with influenza-associated CAP were significantly older, had been vaccinated less often and had preceding antibacterial treatment less often. 30-day mortality was low (4.4%) and not different to that of patients with pneumonia caused by bacterial (6.2%) or viral (other than influenza) pathogens (4%). Patients with influenza plus a bacterial pathogen (mixed influenza-associated pneumonia) had a higher mortality than those with pure influenza-associated pneumonia (9% versus 3.2%). Mortality was higher in patients with mixed compared with pure influenza-associated pneumonia. However, we could not observe any excess mortality in patients with influenza-associated pneumonia.
authors.affiliation: Institute for Medical Microbiology and Hygiene, University Hospital of Ulm, Ulm, Germany. heike.von-baum@uniklinik-ulm.de
authors.forename: H
authors.initials: H
authors.lastname: von Baum
authors.forename: B
authors.initials: B
authors.lastname: Schweiger
authors.forename: T
authors.initials: T
authors.lastname: Welte
authors.forename: R
authors.initials: R
authors.lastname: Marre
authors.forename: N
authors.initials: N
authors.lastname: Suttorp
authors.forename: M W R
authors.initials: MW
authors.lastname: Pletz
authors.forename: S
authors.initials: S
authors.lastname: Ewig
mesh_terms: D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D017714:Community-Acquired Infections / Q000175:diagnosis / Q000188:drug therapy / Q000401:mortality* / Q000821:virology; D005260:Female; D005858:Germany / Q000453:epidemiology; D006801:Humans; D015994:Incidence; D007251:Influenza, Human / Q000175:diagnosis / Q000401:mortality* / Q000821:virology; D008297:Male; D008875:Middle Aged; D011008:Pneumococcal Infections / Q000175:diagnosis / Q000188:drug therapy / Q000401:mortality; D011024:Pneumonia, Viral / Q000175:diagnosis / Q000188:drug therapy / Q000382:microbiology / Q000401:mortality*; D011446:Prospective Studies
chemical_list: D000900:Anti-Bacterial Agents